Lv3
280 积分 2023-07-09 加入
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
13天前
已完结
Immune-Related Adverse Events with PD-1 Versus PD-L1 Inhibitors: A Meta-Analysis of 8730 Patients from Clinical Trials
2个月前
已完结
Evaluation and practical application of prompt-driven ChatGPTs for EMR generation
6个月前
已完结
Timing of Once-Daily Thoracic Radiotherapy and Clinical Outcomes in Patients with Limited-Stage Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
7个月前
已完结
Co-Delivery of VEGF siRNA and THPP via Metal–Organic Framework Reverses Cisplatin-Resistant Non-Small Cell Lung Cancer and Inhibits Metastasis through a MUC4 Regulating Mechanism
9个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
9个月前
已完结
Two Sides to the Story
9个月前
已完结
Immunotherapy for lung cancer
1年前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
1年前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
1年前
已完结
皖公网安备34019202002308
